{"name":"Alebund Pharmaceuticals","slug":"alebund-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP301","genericName":"AP301","slug":"ap301","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"AP301","genericName":"AP301","slug":"ap301","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNdGVUdHIzS0RCMG5pVjZELWJjZVRLQk9WVm8zN0F1LWNMaWRhUFdoeWw5cUFzMjVjbW5ZemRmb2JmMlF4UVJMbndYNmFmMEMxWUJUZWhOZFVKRWVUdFJpa3lya1JrTTgtMFdQNXFoQXBZakc1R2ZVT0tTcFNINmxMMXdiNFZmNmRmc3c?oc=5","date":"2026-03-20","type":"pipeline","source":"pharmaphorum","summary":"Kidney biotech R1's $78m debut, and other biofinancings - pharmaphorum","headline":"Kidney biotech R1's $78m debut, and other biofinancings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOWxvZWZzSUw3Mlh3eWdzUXF5NDJBZXRTclg0Q1pCMkhHY0djb29TU3BfRElZSWgxQXQ0dkJvT3ZCdVdUejhjb1FSMHRJQU1iaTdzVGlHWXVpaW9oMURyR3NkTVloOXpkeThoWndLQlFXQ05ycnE1LVpxR0JpZU5XOHZoZ1RsdFRiWkhqcW9kM0JyUmxzVmtZR0J2aVRJSjF5dXdTN3dBM1Fxbm8wMFVYdUNENkxKdTk2NFk4YTJMQVFjNjFQdHJXZk80SW1fZVl5cXc?oc=5","date":"2026-03-18","type":"deal","source":"BioPharma APAC","summary":"Alebund Partners R1 Therapeutics To Advance AP306 Globally For CKD Related Hyperphosphatemia - BioPharma APAC","headline":"Alebund Partners R1 Therapeutics To Advance AP306 Globally For CKD Related Hyperphosphatemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOU3lsNjVRVXowSGdWZ0plSWhhWUZoWEd0VERldmlWNUNXZl9PMHlqenBnRE9ZR2VTZ1JvMUZFWjllb0NFTnl4LUhBRGxFOVFwTDgzWlBjcWg3VlFVQXhtZDRoZWVrZHVGSnFyN01KR1FJcW4xODlIZkFiWko2M01OSXRMcmhVSVN2b0J2ZmVZVEU1STV5N2dQbjNtdHlwSmdpUjhIQVlNZEM2SXpKVGdiWThuWlBPeUNYZ2RXMjJJVHhSdmVmRWI0ejZuTDl3OXpGbmg1N0UzZExwbjBEb0w4dA?oc=5","date":"2026-02-10","type":"pipeline","source":"Barchart.com","summary":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight - Barchart.com","headline":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOY3UwTFY2ZGI5ZXJNUEJVZ3o0ZThCdTFOWm5uN0t4QU0xOUVrOU8ySndNOER3Y2VhVWlDZUJZcWxlc3FpQUFzNERwdTEzdjJyTllyalNuVmwzbEJzX1RUN3hpUDZWZkg0X3VxZmRfYlhhS1M5VDZrLWRxZEJBdFkzSlpFU2NJY2VnRTBGMl9kT2l1aURLbXhLbGtfQXFqWU0wWllEV2RkdkN0TndsbE1iVzZWX1lReXFYZkNTaVJuQUJlXzFQSi1HNjA0Ti1kaVNDcUE4QXBJZU1OUVV3Znk3aHZjdmxMR0pLYjJMUzhPNE51SlcwVGVZcm5DSFl1UGYwb0t2SmJlM0l6TC16TV8ydTNsZlRqanRhbUxsbk9maU82RVpiSmRzeg?oc=5","date":"2025-06-10","type":"trial","source":"GlobeNewswire","summary":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights - GlobeNewswire","headline":"Diabetic Nephropathy Clinical Trial Analysis: Key Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNZWZLdy1JWEJyZkJwMVVSdHVLWU1NN3djYkZLOXo1eXNIRkc1U0dsOGo5am9xS3V4MEVJSEIyNWFjOEdzLWVnRWltNURhQWhaQkVlY2o4VnMwQTRkU05aSWxVVzR4Rk5aLU96TWtMWV81MlBTZmFkT0dlQ0tJSEtBUVVnNEt1WWM?oc=5","date":"2025-01-08","type":"pipeline","source":"pharmaphorum","summary":"Aviceda raises $207.5m for eye drug, and other financings - pharmaphorum","headline":"Aviceda raises $207.5m for eye drug, and other financings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1DdEJrdlp3Ym1fYUczdkdDOUlRTng0ZXZZMWlRXzQtQUxBT2REM1JOUTB3WVhGUlJrYUdtRzl1MUE1VjBrWVBvbHVubTlaSUJLSjhUSDFCWmdmRUpxejBYd0FOOVAtVkVYbjZlY2FWbzdOTkQwMXR2VQ?oc=5","date":"2024-04-08","type":"pipeline","source":"Straits Research","summary":"Hyperphosphatemia Treatment Market Size, Top Share | Industry Report, 2033 - Straits Research","headline":"Hyperphosphatemia Treatment Market Size, Top Share | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOTG11Z3JLRkd5dXAtME4tM1ZMTzE3aGZGdDdfdDR3ZWw0NmFIOUxSTXFkY0NnSVJwV3FWY0tYOEJJbXRzQm1LMTAtZjc1eTJIRHhZQlJWS1FQQUZsNG9VTGoxNWdhYUNwWnh6Z0xOaGdBa1VlenR3akJuTWZFTDdXaVpTTk1aWVExZDZEYTRvMEJvVFlldno0ejNzTWlqM3NVRFViMWRVNzdTQVdtbmNkRjRRZDBWT2FfXzI0RExkckxUS0UwUXlPVUxqMmRCNXdpU3Uw?oc=5","date":"2024-04-01","type":"regulatory","source":"BioPharma APAC","summary":"Alebund Pharmaceuticals Receives FDA Orphan Drug Designation for AP303 in ADPKD Treatment - BioPharma APAC","headline":"Alebund Pharmaceuticals Receives FDA Orphan Drug Designation for AP303 in ADPKD Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1pbno4WnR6VkFLYjB0WGVpbWZPdHFBME9URl9VUFlvaVRoQ2lIVkJTZG9VWGJDMFFMZ0dsZEZVUkFqaFpGbnl2cFdnekthM0xkRFdLUUhVcVhfOU1nUjd1QmV2bmcya1MwSVo2SnM0aUJ3UDcwOGd4VA?oc=5","date":"2024-04-01","type":"regulatory","source":"Pharmaceutical Technology","summary":"US FDA grants orphan drug designation to Alebund’s AP303 - Pharmaceutical Technology","headline":"US FDA grants orphan drug designation to Alebund’s AP303","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}